Voyager Technologies said its acquisition of ExoTerra Resource positions the company for major national security initiatives such as Golden Dome, while expanding its ability to deliver flight-proven ...

When NASA launched the Voyager 1 probe back in 1977, the initial objective was to gather information about our solar system — specifically, the region beyond the asteroid belt (between the orbits of ...

Voyager 1 is one of humanity's greatest achievements in space travel. This spacecraft was launched by NASA in September 1977 on a one-way trip to the outer reaches of our solar system. Originally, it ...

On September 5, 1977, NASA launched the Voyager 1 probe into space with the aim of studying the outer planets. Voyager 1 launched a couple of weeks after Voyager 2, and both probes have flown to the ...

Voyager Technologies has acquired a proprietary technology from BridgeComm Technologies as part of its effort to accelerate internal development efforts and the delivery of advanced optical ...

The once high-flying crypto lender Voyager Digital Ltd., which filed for Chapter 11 bankruptcy in July 2022, has returned to headlines after its co-founder and former chief executive Stephen Ehrlich ...

The Commodity Futures Trading Commission (CFTC) announced that the U.S. District Court for the Southern District of New York has entered a consent order against Stephen Ehrlich, the former CEO of ...

DENVER--(BUSINESS WIRE)--Voyager Technologies [NYSE: VOYG] acquired ElectroMagnetic Systems, Inc. (EMSI), a California-based premier developer of AI and machine learning-based automated target ...

James is a published author with multiple pop-history and science books to his name. He specializes in history, space, strange science, and anything out of the ordinary.View full profile James is a ...

Voyager Technologies Inc.’s stock skyrocketed on Wednesday following an upsized initial public offering, showing that investors’ appetite for space-industry stocks appears to be growing. Voyager’s ...

Voyager faces a challenging outlook, with a negative enterprise value and declining stock amid industry-wide setbacks in AAV gene therapy. The company's lead asset, VY7523, is early in clinical ...